Institut du Cancer Montpellier
Institut du Cancer Montpellier
Montpellier, France2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-04-17 | NCT06195709 | |
| Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 2 | 2025-03-27 | NCT05955170 |